Men With Breast Cancer Present at Later Stage, Have Worse Prognosis Than Women
At 10 years, the disease-free survival rate was 54.5%, and the overall survival rate was 50.7%.
RSS News Feed
Latest
Induction Chemo Plus CRT More Effective Than CRT Alone in Nasopharyngeal Carcinoma
Induction chemotherapy was associated with improvements in disease-free, failure-free, relapse-free, and progression-free survival.
Obinutuzumab Bests Rituximab in Previously Untreated Follicular Lymphoma
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.
Factors Associated With Non-Small Cell Lung Cancer Stage at Presentation
Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.
Breyanzi Approved as Second-Line Treatment for Large B-Cell Lymphoma
The expanded approval was based on data from the phase 3 TRANSFORM and phase 2 PILOT studies.
Dual Effect Identified for Arsenic in Carcinogenesis
The arsenic level in drinking water was negatively associated with incidences of lymphoma and leukemia in men and women.
Symptoms May Persist After Pediatric SARS-CoV-2 Infection
A large cross-sectional study offered a survey of long COVID symptoms in children who have been infected with SARS-CoV-2.
High-Deductible Health Plans Linked to Delayed Diagnosis of Metastatic Cancer
Having a high-deductible health plan was associated with a nearly 5-month delay in the diagnosis of metastatic cancer.
Rate of CRT-Related Pneumonitis in NSCLC May Be Higher in Real World Than in Clinical Trials
The pooled incidence of chemoradiation-induced grade 3-5 pneumonitis was 3.62% in randomized trials, 5.98% in observational studies, and 7.85% in observational studies of platinum doublet chemotherapy.
Denosumab Improves Long-Term Outcomes in AI-Treated Breast Cancer
Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival.
More African Americans Screened for Lung Cancer With USPSTF 2021 Criteria
African-American patients were more likely to be eligible for lung cancer screening using USPSTF’s 2021 criteria vs 2013 criteria.
Age, Follow-Up Interval Associated With Risk of Breast Cancer-Related Lymphedema After Axillary Lymph Node Dissection
Researchers sought to identify factors that increase the risk of developing breast cancer-related lymphedema in patients who underwent axillary lymph node dissection.
Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors
The accelerated approval was based on data from two phase 2 trials: the ROAR basket study and the NCI-MATCH Subprotocol H study.
U.S. SARS-CoV-2 Seroprevalence High Based on Blood Donations
The combined SARS-CoV-2 seroprevalence from infection or vaccination reached an estimated 94.7% by December 2021.
Opioids and Cancer: How to Prevent and Manage Misuse
Research has revealed patterns of opioid use and misuse in cancer patients and survivors.
Prevalence of Cancer Among Pregnant Patients on the Rise
The prevalence of pregnancy with cancer increased 13.8% from 2016 to 2019.
Predicting Response to COVID-19 Vaccines in Patients With Hematologic Malignancies
Two treatment-related factors and the frequency of 6 cell types were associated with response to COVID-19 vaccination.
Higher Dairy Intake May Up Risk for Prostate Cancer
The association does not hold for nondairy calcium intake.
Dialysis Population Has Excess Cancer Mortality
Patients on dialysis die from cancer at twice the rate as those of the same age and sex in the general population, a study found.
Income, Education Linked to Advanced Stage of Diagnosis of NSCLC
Findings persist across racial/ethnic groups, regardless of government or private insurance, and across facility types.
Medicare Could Have Saved $3.6 Billion on Generic Drugs in 2020
Researchers compared Medicare Part D spending for 89 drugs to prices for their generic equivalents sold by Mark Cuban Cost Plus Drug Company.
Dexamethasone Increases Risk for Superinfections in Patients With Severe COVID-19
Researchers assessed the association between dexamethasone treatment and the occurrence of superinfections among patients with severe COVID-19.
Nab-Paclitaxel Plus Pembrolizumab in HR+ Breast Cancer
Researchers are conducting a phase 1 trial of nab-paclitaxel and pembrolizumab in patients with hormone receptor-positive breast cancer.
RGT-419B Alone or With Hormone Therapy in HR+/HER2- Advanced Breast Cancer
Researchers are conducting a phase 1 trial to evaluate RGT-419B, a CDK2/4/6 inhibitor, in patients with HR+, HER2-, stage III/IV breast cancer.
Adding Simvastatin to Anti-HER2 Therapy for Metastatic Breast Cancer
Researchers are conducting a phase 2 trial to determine if adding simvastatin to dual anti-HER2 therapy will induce a response after progression of HER2+ metastatic breast cancer.
Using ctDNA to Guide Second-Line Therapy in ER+/HER2- Breast Cancer
Researchers aim to determine if ctDNA testing can guide second-line adjuvant therapy in high-risk, stage II-III, ER+, HER2- breast cancer.
USPSTF: Do Not Take Vitamin E, Beta Carotene to Prevent Cancer
Vitamin E does not decrease the risk of cancer or cancer-related death, and the risk of harm from beta carotene outweighs any potential benefits, according to the USPSTF.
LDCT Screening Tied to Lower Incidence of Advanced Lung Cancer
The incidence of advanced lung cancer declined by 3 cases per 100,000 people per year in 2015-2018 relative to 2004-2014.
Camrelizumab, Apatinib, and Temozolomide Combo Produces Durable Responses in Acral Melanoma
The overall response rate was 66.7%, and the median duration of response was 17.5 months.
Treating Anal HSIL Cuts Anal Cancer Risk in Persons With HIV
The rate of progression to anal cancer was lower for patients receiving treatment for anal high-grade squamous intraepithelial lesions.
Half of Hospitals Have Implemented No Price Transparency
Only 5.7% of hospitals met both requirements, which are a machine-readable file for required price types and an accessible display for at least 300 shoppable items.
Disruption to Oncology Clinical Trials Seen Early in Pandemic
Numbers of new patient accruals and newly activated trials decreased early on, followed by a progressive recovery and return to levels that were higher than normal.
COVID-19 Vaccine Candidate Nanocovax Induces Robust Immunity
Researchers assessed the safety and immunogenicity of Nanocovax, a novel COVID-19 vaccine candidate.
Treatment Advances for Metastatic Breast Cancer Tied to Decrease in Deaths
Among patients with ER+/HER2+ breast cancer, the median survival after distant recurrence increased from 2.3 years in 2000 to 4.8 years in 2019.
Acupuncture Improves Symptoms of Radiation-Induced Xerostomia in Head and Neck Cancer
Acupuncture was associated with improvements in symptoms and quality of life.
Bariatric Surgery Cuts Obesity-Related Cancer Incidence
The cumulative incidence of obesity-related cancers at 10 years was 2.9% in the bariatric surgery group and 4.9% in the nonsurgical control group.
Federal Court Orders EPA to Reexamine Whether Roundup Causes Cancer
In its ruling, the court challenged the Trump-era finding that glyphosate was not a serious health risk and “not likely” to cause cancer.
Study Compares DBT With Digital Mammography Screening
Use of digital breast tomosynthesis was associated with a lower risk of advanced breast cancer for certain patients.
Mixed Results for Paxlovid in Standard-Risk Patients With COVID-19
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
Trabectedin No Better Than Physician’s Choice in Recurrent Ovarian Cancer
There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
New Cancer Drugs Approved Faster in U.S. Than Europe
The FDA received licensing applications sooner and had shorter review times, compared to the European Medicines Agency.
Rivoceranib Appears Active in Recurrent, Metastatic Adenoid Cystic Carcinoma
Rivoceranib produced responses whether or not patients had received prior treatment with a VEGFR TKI.
Higher Fish Intake May Increase Melanoma Risk
Higher total fish intake, tuna intake, and nonfried fish intake were all positively linked to the risk of malignant melanoma and melanoma in situ.
Features of Fever of Unknown Origin Later Diagnosed as Lymphoma
Researchers sought to define clinical and prognostic features associated with fever of unknown origin in patients later diagnosed with lymphoma.
Risk of New-Onset Type 2 Diabetes Up After Cancer Diagnosis
There was an increased risk of new-onset type 2 diabetes in patients with pancreatic, brain/central nervous system, endometrial, lung, urinary tract, and breast cancers.
One in Nine May Get Delayed Large Local Reaction After Moderna Vaccine
There was a higher risk for DLLR seen among women and among individuals aged 30 to 69 years.
Repotrectinib Plus Chemotherapy in Patients With Relapsed/Refractory Solid Tumors
Researchers are conducting a phase 1/2 trial to assess the safety and efficacy of combination repotrectinib, irinotecan, and temozolomide.
RRx-001 Plus Chemotherapy in Recurrent/Progressive Solid Tumors
Researchers are conducting a phase 1 trial to assess the safety and efficacy of RRx-001 in combination with irinotecan and temozolomide.
Ibrutinib Plus Chemoimmunotherapy for Patients With Brain Cancer
Researchers are conducting a phase 1 trial of ibrutinib plus indoximod, cyclophosphamide, and etoposide in patients with brain cancers.
Nivatrotamab in Patients With Relapsed/Refractory Solid Tumors
Researchers will assess toxicity and pharmacokinetics in phase 1 and the antitumor activity of nivatrotamab in phase 2.
Violating Patient Confidentiality Is Sometimes Necessary
Patients trust that what they tell their doctors will remain confidential, but under certain specific circumstances, the doctors may be obligated to breach that trust.
Sugar-Sweetened Drinks May Raise Risk for Liver Cancer
Replacing sugar-sweetened beverages with water and non-sugar-sweetened coffee or tea could significantly lower liver cancer risk, researchers said.
AACR: Cancer Disparities Represent Ongoing Public Health Challenge
Discriminatory policies, systemic inequities, and structural barriers resulting from the history of racism cause and perpetuate cancer health disparities.
Healthy Plant-Based Diet May Cut Breast Cancer Risk
Adherence to a healthful plant-based food diet is associated with a reduced risk of breast cancer for postmenopausal women, a study suggests.
Additional Biopsies After CRC Biopsy Not Tied to Metachronous CRC
Biopsy of nontumor sites after initial colorectal cancer biopsy was not linked to a risk for metachronous cancer.
Screening Mammography Levels Not Fully Restored After Pandemic Drop
While mammography, biopsies, and cancer diagnoses are up from 2020 lows, none have reached pre-COVID-19 volumes.
Omitting Node Dissection, Adjuvant Therapy May Be Safe for Some With Stage III Melanoma
The estimated 2-year RFS rate for patients with MPR was 93.3% (95% CI, 87.2%-99.9%) after a median follow-up of 27.9 months.
Durability of mRNA-1273 Protection Against Symptomatic COVID-19 Examined
Among patients receiving 2 doses, peak vaccine efficacy against symptomatic COVID-19 was estimated to be 94.1% at 120 days after the first dose.
Neoadjuvant Pembrolizumab in Resectable Desmoplastic Melanoma Leads to High pCR Rate
The study population included patients aged 18 years and older who had histologically confirmed desmoplastic melanoma that was resectable.
Triple Combination Active Against CNS Metastases of BRAFV600-Mutated Melanoma
The 3-drug strategy combines targeted therapy against BRAF (vemurafenib) and MEK (cobimetinib), and immunotherapy (atezolizumab).
Toripalimab With Axitinib Active in Treatment-Naive Advanced Mucosal Melanoma
Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.
Camrelizumab, Apatinib, Temozolomide Combination Is Efficacious for Acral Melanoma
In all, 32 patients had a response, translating to an ORR of 66.7%.
Upfront Radiotherapy May Benefit Medulloblastoma Patients With Li-Fraumeni Syndrome
Patients with sonic hedgehog medulloblastoma and Li-Fraumeni syndrome have a “dismal” prognosis, according to researchers.
Reinduction Regimen Appears Effective in Children With Relapsed Medulloblastoma
The overall response rate after 2 treatment cycles was 78%.
Acalabrutinib Is Highly Active Chemotherapy-Free Alternative for Marginal Zone Lymphoma
Among the TEAEs of clinical interest, the most frequent were infections, bleeding, cardiac events, anemia, and neutropenia and neutrophil count decrease.
Parsaclisib is a Potential Third-Line Therapy for Follicular Lymphoma
Parsaclisib is a potent, highly selective, next-generation phosphoinositide 3-kinase-delta (PI3K-delta) inhibitor.
Safety and Efficacy of Sugemalimab in Extranodal Natural Killer/T-Cell Lymphoma
Based on preliminary data from this study, sugemalimab was granted breakthrough therapy designation for adult patients with R/R ENKTL in 2021.
Safety and Efficacy of a CD20-CD3-Specific Antibody Therapy for DLBCL
At a median follow-up of 12.6 months, the overall response rate was 51.6% and the CR rate was 39.4%.
Brentuximab Vedotin Improves Outcomes in Pediatric High-Risk Classic Hodgkin Lymphoma
Results of a phase 3 trial suggest that brentuximab vedotin (Bv) with doxorubicin (A), vincristine (V), etoposide (E), prednisone (P), and cyclophosphamide (C) should be the new standard frontline therapy among youth with high-risk classic Hodgkin lymphoma (cHL).
RNA Sequencing Reveals Clinically Relevant Alterations in Pediatric Low-Grade Glioma
RNA sequencing confirmed the alterations most frequently described in low-grade glioma and revealed rare gene fusions.
Molecular Analysis Refines Diagnosis, Enables Personalized Treatment for Pediatric CNS Tumors
Of the patients who completed follow-up, 60% had a targeted therapy recommendation.
Larotrectinib Produces “Remarkable” Responses in NTRK Fusion-Positive CNS Tumors
The median duration of response was not reached at a median follow-up of 26 months.
Asciminib Continues to Demonstrate Superior Efficacy for CML-CP
The patients were randomly assigned 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily.
Increased Stage I Lung Cancer Diagnoses Driven by NSCLC
The percentage of patients with stage I disease increased from 23.5% in 2010 to 29.1% in 2017.
Longer Deep Molecular Remission in CML Associated With Treatment-Free Remission
The investigators performed univariate and multivariate analyses to identify factors associated with the loss of MMR.
Amivantamab-Lazertinib Active in EGFR-Mutant NSCLC After Exhausting Standard Care Options
The overall response rate was 33%, with 1% of patients having complete responses and 32% having partial responses.
Chemo-Immunotherapy May Have Edge in Advanced NSCLC With Higher PD-L1
Results showed a median overall survival of 25.0 months for chemo-immunotherapy vs 20.9 months for immunotherapy alone.
Adagrasib Promising in KRASG12C-Mutated NSCLC
The researchers noted that responses were deep, with 75% of responders achieving a greater than 50% tumor reduction.
Eftilagimod Alpha, Pembrolizumab Combo Encouraging in PD-L1-Unselected NSCLC
TACTI-002, enrolled 114 patients with untreated locally advanced or metastatic non-small cell lung cancer, unselected for PD-L1 expression.
Trends in Second Malignancy and Mortality Risk After Primary Chronic Myeloid Leukemia
In CML, second malignancies are rare and trends remain poorly understood.
Use of Oral Tyrosine Kinase Inhibitors for R/R CML Increasing Over Time
From 2017 to 2019, the number of beneficiaries prescribed at least 1 oral TKI increased from 154 beneficiaries to 212 beneficiaries.
CML Does Not Affect Antibody Development Against SARS-CoV-2
Investigators reported findings from the ongoing SARS2 SeroPrevalence And Respiratory Tract Assessment (SPARTA) study.
Whole Ventricular Radiotherapy Alone Can Maintain CR in Patients With Localized Germinoma
Of the 65 patients who achieved a complete remission with chemotherapy, 63 remained in remission after whole ventricular radiotherapy and at the final follow-up.
Temozolomide Radiochemotherapy May Provide Benefit in High-Grade Glioma
The treatment proved noninferior to cisplatin-based radiochemotherapy.
Proton Therapy vs IMRT: Similar Risk of Secondary Neoplasms in CNS Tumor Survivors
There was no significant difference in rates of secondary neoplasms at 10 years.
Researchers Characterize Treatment Failure in CNS Non-Germinomatous Germ Cell Tumors
Metastatic relapse was associated with elevated tumor markers, but it was not associated with focal or whole ventricular radiotherapy.
Black Patients With Medulloblastoma Have Higher Risk of Death
Hispanic and non-Hispanic patients had a similar risk of death.
Extended Decitabine Appears Safer Than Standard Induction for Older AML Patients
Extended decitabine produced a similar overall survival rate as standard chemotherapy, but decitabine had a better safety profile.
Response to Axicabtagene Ciloleucel Superior to Standard Care in R/R Large B-Cell Lymphoma
Axi-cel improved event-free survival vs standard care in older patients with relapsed/refractory large B-cell lymphoma.
Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Health Care Providers Lack Knowledge About Pediatric CNS Tumors, Survey Suggests
A global survey of health care providers revealed significant knowledge gaps about childhood central nervous system tumors.
Survivors of Medulloblastoma Have Greater Risk of Stroke, Severe Hearing Loss
Medulloblastoma survivors had an increased risk of long-term adverse outcomes.
Late Outcomes Support Radiation-Limiting Treatment Strategies for Pediatric Glioma
Use of radiation decreased over time, while use of surgery alone increased.
High Risk of Endo-Metabolic and Neuro-Behavioral Comorbidities in Optic Pathway Glioma Survivors
The etiology of comorbidities depends on hypothalamic tumor location and treatments received.
No Clinical Benefit With Nivolumab or Nivo-Ipi in Pediatric Patients With CNS Cancer
Nivolumab alone or in combination with ipilimumab did not improve outcomes compared with historical data.
Bortezomib Provides No Benefit Over R-DHAP Alone in R/R DBLCL
Overall, there was no improvement in complete response or survival outcomes among patients who received bortezomib.
Orelabrutinib-Sintilimab Yields Responses in Primary CNS Lymphoma
The overall response rate at cycle 4 was 61.5%, and none of these patients relapsed.
DA-EPOCH-R No More Effective Than R-CODOX-M/R-IVAC in Burkitt Lymphoma
The 2 regimens produced similar efficacy outcomes, but adverse events were more common in the R-CODOX-M/R-IVAC arm.
Quizartinib Improves Overall Survival in FLT3-ITD+ Acute Myeloid Leukemia
Results from the phase 3 QuANTUM-First trial have the potential to change standard care for adults with newly diagnosed FLT3-ITD+ acute myeloid leukemia, according to the lead study author.
Academic BCMA CAR T-Cell Therapy “Promising” in Rel/Ref Multiple Myeloma
The overall response rate was 100%, and the 18-month progression-free survival rate was 53%.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...